v3.25.2
Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2025
Accounting Policies [Abstract]  
Research and Development Expense for Major Programs
The following table sets forth significant research and development (“R&D”) expenses by program as regularly provided to the CODM (in thousands):

Three Months Ended 
June 30,
Six Months Ended 
June 30,
2025202420252024
Birtamimab (NEOD001)
$19,433 $21,565 $45,347 $42,749 
PRX012
15,093 31,994 33,168 69,807 
PRX019
1,824 676 3,926 1,457 
Other R&D
4,167 3,275 8,887 7,611 
Total R&D
$40,517 $57,510 $91,328 $121,624